Latest Payments News

Farm Pride Foods has successfully recovered from Avian Influenza setbacks, improving cash flows and repaying significant debt while investing in biosecurity and production upgrades.

Suvo Strategic Minerals delivered a robust December quarter with soaring profits and an extended supply deal, while advancing innovative low carbon cement projects in Australia and Indonesia.

Marvel Gold reports a cautious quarter with $0.513 million cash on hand and ongoing negotiations over its Mali assets, while actively exploring new opportunities beyond Mali for sustainable growth.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

FirstWave reports a stable Q2 FY25 with no cash burn for the second consecutive quarter, maintaining cash reserves at $1.68 million while securing key client contract renewals and launching a promising new product.

Resolute Mining delivered a solid 2024 with record cash flows and slightly higher gold production, but faces rising costs from Mali’s new Mining Code and a $160 million government settlement. The company plans lower 2025 output as Mako mining winds down, focusing on cash flow and exploration.

ioneer Ltd’s December 2024 quarterly cash flow report reveals ongoing cash outflows from operations and investing, with nearly $4.5 million spent this quarter but a solid cash reserve providing a runway of almost five quarters.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

Visionflex Group Limited reported a net cash outflow from operations for the December 2024 quarter but secured significant financing, extending its funding runway to nearly 15 quarters.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.